

Dr. med. Eva Ebnöther

Kardiovaskuläres Risiko von Diabetikern wirksam senken

Bibliografie

- ¹ Ray KK, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet* 2009; 373(9677): 1765–1772.
- ² Zinman B, et al.: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2015; 373(22): 2117–2128.
- ³ Marso SP, et al.: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016; 375(4): 311–322.
- ⁴ D’Aiuto et al.: Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. *Lancet Diabetes* 2018; 6(12): 954–965.
- ⁵ Pavlović A, et al.: Longterm mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. *Eur J Prev Cardiol* 2019 Jan; 26(1): 72–82.
- ⁶ ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2013; 34(39): 3035–3087.

- ⁷ Packer M: Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. *J Am Coll Cardiol* 2018; 71(20): 2360–2372.
- ⁸ Jorsal A, et al.: Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. *Eur J Heart Fail* 2017; 19(1): 69–77.
- ⁹ Margulies KB et al.: Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. *JAMA*. 2016; 316(5): 500–508.
- ¹⁰ Marso SP, et al.: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med* 2016; 375(19): 1834–1844.
- ¹¹ Neal B, et al.: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med*. 2017; 377(7): 644–657.
- ¹² Wiviott SD, et al.: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2019; 380(4): 347–357.
- ¹³ Cosentino F, et al.: Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. *Eur Heart J* 2018. doi: 10.1093/eurheartj/ehy677.